Literature DB >> 29950321

Mitochondrial DNA replication: clinical syndromes.

Mohammed Almannai1, Ayman W El-Hattab2, Fernando Scaglia3,4,5.   

Abstract

Each nucleated cell contains several hundreds of mitochondria, which are unique organelles in being under dual genome control. The mitochondria contain their own DNA, the mtDNA, but most of mitochondrial proteins are encoded by nuclear genes, including all the proteins required for replication, transcription, and repair of mtDNA. MtDNA replication is a continuous process that requires coordinated action of several enzymes that are part of the mtDNA replisome. It also requires constant supply of deoxyribonucleotide triphosphates(dNTPs) and interaction with other mitochondria for mixing and unifying the mitochondrial compartment. MtDNA maintenance defects are a growing list of disorders caused by defects in nuclear genes involved in different aspects of mtDNA replication. As a result of defects in these genes, mtDNA depletion and/or multiple mtDNA deletions develop in affected tissues resulting in variable manifestations that range from adult-onset mild disease to lethal presentation early in life.
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  DNA replication and recombination; mitochondria; mitochondrial dysfunction; mtDNA

Mesh:

Substances:

Year:  2018        PMID: 29950321     DOI: 10.1042/EBC20170101

Source DB:  PubMed          Journal:  Essays Biochem        ISSN: 0071-1365            Impact factor:   8.000


  9 in total

Review 1.  Mitochondrial Membranes and Mitochondrial Genome: Interactions and Clinical Syndromes.

Authors:  Mohammed Almannai; Azza Salah; Ayman W El-Hattab
Journal:  Membranes (Basel)       Date:  2022-06-15

2.  Most mitochondrial dGTP is tightly bound to respiratory complex I through the NDUFA10 subunit.

Authors:  Yolanda Cámara; Ramon Martí; David Molina-Granada; Emiliano González-Vioque; Marris G Dibley; Raquel Cabrera-Pérez; Antoni Vallbona-Garcia; Javier Torres-Torronteras; Leonid A Sazanov; Michael T Ryan
Journal:  Commun Biol       Date:  2022-06-23

Review 3.  DNA-editing enzymes as potential treatments for heteroplasmic mtDNA diseases.

Authors:  U Zekonyte; S R Bacman; C T Moraes
Journal:  J Intern Med       Date:  2020-04-27       Impact factor: 8.989

Review 4.  Applying genomic and transcriptomic advances to mitochondrial medicine.

Authors:  William L Macken; Jana Vandrovcova; Michael G Hanna; Robert D S Pitceathly
Journal:  Nat Rev Neurol       Date:  2021-02-23       Impact factor: 42.937

5.  A Screen Using iPSC-Derived Hepatocytes Reveals NAD+ as a Potential Treatment for mtDNA Depletion Syndrome.

Authors:  Ran Jing; James L Corbett; Jun Cai; Gyda C Beeson; Craig C Beeson; Sherine S Chan; David P Dimmock; Lynn Lazcares; Aron M Geurts; John J Lemasters; Stephen A Duncan
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

6.  Mild myopathic phenotype in a patient with homozygous c.416C > T mutation in TK2 gene.

Authors:  George K Papadimas; Efthimia Vargiami; Pinelopi Dragoumi; Rudy Van Coster; Joel Smet; Sara Seneca; Constantinos Papadopoulos; Evangelia Kararizou; Dimitrios Zafeiriou
Journal:  Acta Myol       Date:  2020-06-01

7.  A novel homozygous variant in MICOS13/QIL1 causes hepato-encephalopathy with mitochondrial DNA depletion syndrome.

Authors:  Yoshihito Kishita; Masaru Shimura; Masakazu Kohda; Masumi Akita; Atsuko Imai-Okazaki; Yukiko Yatsuka; Yoko Nakajima; Tetsuya Ito; Akira Ohtake; Kei Murayama; Yasushi Okazaki
Journal:  Mol Genet Genomic Med       Date:  2020-08-04       Impact factor: 2.183

Review 8.  Clinical trials in mitochondrial disorders, an update.

Authors:  Mohammed Almannai; Ayman W El-Hattab; May Ali; Claudia Soler-Alfonso; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2020-10-06       Impact factor: 4.797

9.  RNase H1 Regulates Mitochondrial Transcription and Translation via the Degradation of 7S RNA.

Authors:  Aurelio Reyes; Joanna Rusecka; Katarzyna Tońska; Massimo Zeviani
Journal:  Front Genet       Date:  2020-01-31       Impact factor: 4.772

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.